Thursday, June 15, 2017

Australian patent on CRISPR to MilliporeSigma

From GEN:

MilliporeSigma, the life science business of Merck KGaA, said today it has been awarded its first patent for CRISPR technology—an Australian patent relating to the use of CRISPR in a genomic integration method for eukaryotic cells.
Patent Application No. 2013355214 was filed December 5, 2013, and accepted on May 22, according to an online search of the Australian Patent Office’s online database AusPat. The patent consists of 14 method claims.

MilliporeSigma said in May that it had developed the alternative CRISPR genome-editing method, called proxy-CRISPR, a month after publishing the results of its research in Nature Communications. According to the company, proxy-CRISPR differs from other genome editing systems in its ability to cut previously unreachable cell locations, making CRISPR more efficient, flexible, and specific, and giving researchers more experimental options.

Since 2012, MilliporeSigma has filed multiple CRISPR patent filings, including its filings related to proxy-CRISPR technology.



Post a Comment

<< Home